Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

333
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
333
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

398
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
398
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
Drug Nomenclature01:17

Drug Nomenclature

3.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.7K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

353
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
353
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At the crossroads of senescence and immunosuppression: Machine learning and multi-omics unveil the central role of FAP in HNSCC.

Bioorganic chemistry·2026
Same author

Spatiotemporal flux breathing and topological sculpting in structured transverse orbital angular momentum lattices.

Nature communications·2026
Same author

From blueprint to build: Metal ions in peripheral nerve development and engineering regeneration.

Bioactive materials·2026
Same author

Pharmacovigilance Analysis of Drug-Induced Stomatitis: Insights From Twenty-One Years of Real-World Data.

International dental journal·2026
Same author

Age-Driven Proteomic Networks in Ningxiang Pig Backfat Identify Candidate Regulators of Carcass Traits.

Animals : an open access journal from MDPI·2026
Same author

Harnessing spatiotemporal melatonin delivery from engineered platforms for targeted microenvironment remodeling in peripheral neuropathy.

Materials today. Bio·2026

Related Experiment Video

Updated: Apr 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Implementing drug data exclusivity in China: a comparative analysis with global practices.

Yu Chen1, Xufeng Lv1, Yun Li1

  • 1Center for Drug Evaluation, National Medical Products Administration, China.

Drug Discovery Today
|April 5, 2026
PubMed
Summary
This summary is machine-generated.

China is implementing a new drug data exclusivity system, balancing global intellectual property standards with domestic needs. This system aims to protect innovation while considering generic drug accessibility and AI-generated data challenges.

Keywords:
Data exclusivityData protectionData protection regimeData protection systemDrug data exclusivityDrug data protectionExclusivityMarket exclusivity

More Related Videos

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

2.2K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K

Related Experiment Videos

Last Updated: Apr 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

2.2K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K

Area of Science:

  • Pharmaceutical Policy
  • Intellectual Property Law
  • Health Economics

Background:

  • China is establishing a drug data exclusivity system, aligning with global pharmaceutical intellectual property standards.
  • Existing data exclusivity frameworks in the US, Canada, EU, and Japan provide context for China's upcoming policies.
  • Understanding these systems is crucial for pharmaceutical innovation and market access.

Purpose of the Study:

  • To provide a comprehensive overview and comparative analysis of China's drug data exclusivity system.
  • To evaluate China's proposed framework against international intellectual property norms, specifically the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
  • To identify potential challenges and implications of China's system for stakeholders.

Main Methods:

  • Comparative analysis of international data exclusivity systems (US, Canada, EU, Japan).
  • Detailed examination of China's forthcoming policies, including exclusivity periods, protection mechanisms, and objectives.
  • Evaluation of China's framework against TRIPS standards regarding scope and methods of protection.

Main Results:

  • China's system shows alignment with TRIPS in protection scope and methods.
  • Key aspects of China's system include defined exclusivity periods, specific protection mechanisms, and clear protection objectives.
  • Potential challenges identified include impacts on generic drug accessibility, protection of AI-generated data, and policy overlap risks.

Conclusions:

  • China's drug data exclusivity regime represents a strategic balance between international intellectual property norms and domestic industrial realities.
  • The system's success will depend on effectively navigating challenges related to generic competition and evolving data generation technologies.
  • Further analysis is needed to fully understand the long-term implications for pharmaceutical innovation and patient access in China.